Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada Mumbai, Geneva


Montreal, May 09, 2019 -Lupin Limited (Lupin) and Aptissen S.A. (Aptissen) announced that they have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Based on Statistics Canada, Osteoarthritis affects more than 10% of Canadians aged 15 or older.

Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already approved by Health Canada and an additional strength is currently under review.

Commenting on this development, Dr. Sofia Mumtaz, President of Lupin Pharma Canada stated, “We are pleased to partner with Aptissen for marketing and distribution of Synolis VA, a branded product in Canada. This partnership helps us expand our product portfolio in the Canadian market. We remain committed to bring superior medical products and leverage our distribution strength to allow easy access to specialty medicines in the market.”

About Aptissen:

Aptissen S.A. is a Swiss company founded in 2013 as a spin-off of ANTEIS and is based in the Geneva area, Switzerland. Specialized in the development and commercialization of biopolymer-based medical devices, Aptissen’s founders have developed for the past 25 years the best quality injectable products which meet both patients and doctors’ expectations. Today, Aptissen is evolving in the viscosupplementation market, estimated to be worth $ 3.5Bn through its presence in more than 50 countries worldwide.

Aptissen revolutionized the market by launching Synolis VA the first intra-articular injection which combines Hyaluronic Acid (HA) with antioxidant (Sorbitol). Synolis VA is indicated for the symptomatic treatment of Osteoarthritis to reduce pain and improve mobility. In addition to that, the Aptissen team is focusing on the development of next-generation injectable devices to treat joints diseases.

For more information, please visit: http://www.aptissen.com/ and http://www.synolis.com/ You could also follow us on LinkedIn. New content each week: https://www.linkedin.com/company/aptissen

About Lupin Limited:

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company in terms of market capitalization (28th December 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th September 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT December 2018); 3rd largest Indian pharmaceutical company by global revenues (30th September 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT December 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT December 2018).

For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs.155,598 million (USD 2.41 billion) and Rs.13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Comment